Cyclacel reports Q3 net loss of $6.1M; cash runway only through end of 2023

Bio Green Med Solution, Inc.

Cash equivalents $5.9M at Sep 30, 2023, down from $18.3M at Dec 31, 2022.
Net loss of $6.1M for Q3 2023 vs $5.1M in Q3 2022; R&D spend rose to $5.2M.
Available cash funds planned programs only through end of 2023; discretionary cuts could extend into Q2 2024.
Fadraciclib dose escalation near RP2D selection; plogosertib recruiting at dose level 5 with epigenetic mechanism under study.
UK R&D tax credits reduced to $0.6M in Q3 2023 from $1.0M due to legislative changes.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Bio Green Med Solution, Inc. reported third quarter ended September 30, 2023 results: net income $6.1 million.

Period: third quarter ended September 30, 2023
Net income: $6.1 million
Result: reported results

Exact text from the filing

Net loss for the three months ended September 30, 2023, was $6.1 million, compared to $5.1 million for the same period in 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Bio Green Med Solution, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-117199

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.